N@N

BIOSANTE PHARMACEUTICALS INC (NASDAQ:BPAX), Down By 5.14% ($0.04) From $0.740 After BUYINS.NET Report Predicted Weakness After

^{Published on 2012-03-19 13:40:23 - WOPRAI}
 

March 19, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Tuesday, March 13th 2012 stating that BIOSANTE PHARMACEUTICALS INC (NASDAQ:BPAX) was expected to be Down After its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=bpax&id=253193

At the time this story was written, BIOSANTE PHARMACEUTICALS INC (NASDAQ:BPAX) is Down By 5.14% ($0.04) From $0.740 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

BIOSANTE PHARMACEUTICALS INC (NASDAQ:BPAX) - BioSante Pharmaceuticals, Inc., a specialty pharmaceutical company, develops products for female sexual health and oncology. Its lead products include LibiGel (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD), which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) special protocol assessment; and Elestrin (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSantes licensee. The company is also developing a portfolio of cancer vaccines, three of which have been granted orphan drug designation, and are currently in various Phase II clinical trials. Its other products in development comprise Bio-T-Gel, a testosterone gel for male hypogonadism, or testosterone deficiency in men, which is licensed to Teva Pharmaceuticals; and The Pill-Plus that is a combination of estrogens, progestogens, and androgens for the treatment of female sexual dysfunction in women using oral or transdermal contraceptives, in Phase II clinical development using BioSante patented technology. In addition, the company is developing its calcium phosphate technology for aesthetic medicine, as well as seeking opportunities for its 2A/Furin and other technologies. BioSante Pharmaceuticals, Inc. was founded in 1996 and is based in Lincolnshire, Illinois.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BIOSANTE PHARMACEUTICALS INC (NASDAQ:BPAX) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net